Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview

12112studies shown

Showing 3,457-3,468 of 12,112

Other study type icon

RecruitingNCT07467993

Safety, Tolerability, and Treatment Response of GXV813 for schizophrenia

This study is recruiting in the United States. It is testing Safety, Tolerability, and Treatment Response of GXV813 for schizophrenia.

Multiple locations, including Bentonville

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Novartis Pharmaceuticals
Condition: Schizophrenia

Drug study icon

RecruitingNCT07565428

Roluperidone for schizophrenia

This study is recruiting in the United States. It is testing roluperidone for schizophrenia.

Multiple locations, including Gaithersburg

SchizophreniaOtherFrom 18 Years to 55 Years

Countries: United States
Sponsor: Minerva Neurosciences
Condition: Schizophrenia

Other study type icon

RecruitingNCT07363577

LB-102 for schizophrenia

This study is recruiting in the United States. It is testing LB-102 for schizophrenia.

Multiple locations, including Bentonville

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: LB Pharmaceuticals Inc.
Condition: Schizophrenia

Device study icon

RecruitingNCT06088121

ATNC-MDD V1(TMS With Cognitive Training) for Mental health

This study is recruiting in South Korea. It is testing ATNC-MDD V1(TMS With Cognitive Training) for Mental health.

Multiple locations, including Incheon

Mental healthOtherFrom 60 Years to 85 Years

Countries: South Korea
Sponsor: Advanced Technology & Communications
Condition: Mental health

Other study type icon

RecruitingNCT07221578

VQW-765 for anxiety

This study is recruiting in the United States. It is testing VQW-765 for anxiety.

Multiple locations, including Phoenix

AnxietyOtherFrom 18 Years to 65 Years

Countries: United States
Sponsor: Vanda Pharmaceuticals
Condition: Anxiety

Drug study icon

RecruitingNCT05303064

Weight Gain for schizophrenia

This study is recruiting in the United States, in Argentina, in Brazil, .... It is testing weight Gain for schizophrenia.

Multiple locations, including Dothan

Bipolarity, SchizophreniaDrugFrom 10 Years to 17 Years

Countries: United States, Argentina, Brazil, ...
Sponsor: Alkermes, Inc.
Condition: Bipolarity, Schizophrenia

Other study type icon

RecruitingISRCTN18262237

Study to investigate the safety of ENX-101 and how well it works in healthy volunteers.

This study is recruiting. It focuses on anxiety and currently lists participation information in the Netherlands.

In Netherlands

AnxietyOtherFrom 18 Years to 55 Years

Countries: Netherlands
Sponsor: Engrail Therapeutics, Inc.
Condition: Anxiety

Drug study icon

RecruitingNCT07247968

Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study

This study is recruiting. It focuses on depression and currently lists participation information in China.

In Chongqing

DepressionDrugFrom 13 Years to 17 Years

Countries: China
Sponsor: Min Su
Condition: Depression

Drug study icon

RecruitingNCT07639359

Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

This study is recruiting. It focuses on depression and currently lists participation information in Argentina and the United States.

Multiple locations, including Jacksonville

DepressionOtherFrom 18 Years to 99 Years

Countries: United States, Argentina
Sponsor: Hospital Italiano de Buenos Aires
Condition: Depression

Other study type icon

RecruitingNCT07492537

SUBDIMA: Subclinical Depression in Acute Myocardial Infarction (SUBDIMA25)

This study is recruiting. It focuses on depression and currently lists participation information in Italy.

In Roma

DepressionOtherOver 18 Years

Countries: Italy
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Condition: Depression

Drug study icon

RecruitingISRCTN46365995

Subjective well-being, craving for Cannabis and compliance or medication switch in a double blind study with Olanzapine and Risperidone

This study is recruiting in the Netherlands. It focuses on Schizophrenia.

In Netherlands

SchizophreniaOtherOver 18 Years

Countries: Netherlands
Sponsor: Academic Medical Centre (AMC) (The Netherlands)
Condition: Schizophrenia

Other study type icon

RecruitingISRCTN42939142

Suicide prevention for Emergency Department attendees with substance misuse

This study is recruiting. It focuses on suicide prevention and currently lists participation information in the United Kingdom.

In United Kingdom

Suicidality, AddictionOtherOver 18 Years

Countries: United Kingdom
Sponsor: University of Bristol
Condition: Suicidality, Addiction

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.